Neulasta

Latest stories

2d
The Tampa Tribune
Amgen posts 1Q sales, profit jumps, raises profit forecaststhe first quarter, up 24 percent from last year due to a price hike and wholesa
Amgen posts 1Q sales, profit jumps, raises profit forecasts
The Tampa Tribune / Posted 2 days ago
the first quarter, up 24 percent from last year due to a price hike and wholesalers stocking more inventory. Anemia drugs Neulasta and Aranesp saw sales rise 4 percent to $1.2 billion and 11 percent to $532 million, respectively. Aranesp, a newer,... Read more
6 related stories
3d
Connecticut Post
Amgen posts 1Q sales, profit jumps, raises profit forecaststhe first quarter, up 24 percent from last year due to a price hike and wholesa
Amgen posts 1Q sales, profit jumps, raises profit forecasts
Connecticut Post / Posted 3 days ago
the first quarter, up 24 percent from last year due to a price hike and wholesalers stocking more inventory. Anemia drugs Neulasta and Aranesp saw sales rise 4 percent to $1.2 billion and 11 percent to $532 million, respectively. Aranesp, a newer,... Read more
6 related stories
16d
San Antonio Express-News
15 Reasons to Buy Pfizer and Never Selltake market share from some of the biggest blockbusters. We're talking about ca
15 Reasons to Buy Pfizer and Never Sell
San Antonio Express-News / Posted 16 days ago
take market share from some of the biggest blockbusters. We're talking about cancer drugs Herceptin, Avastin, Rituxan and Neulasta, as well as the best-selling drug in the world, Humira. Biosimilars could be a major growth driver for Pfizer over... Read more
26d
San Antonio Express-News
Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buysfuture is less certain than Gilead's, but at about 16.5 times trailing earnings
Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys
San Antonio Express-News / Posted 26 days ago
future is less certain than Gilead's, but at about 16.5 times trailing earnings it's far more expensive. Enbrel and Neulasta combined for about 48% of Amgen's product sales last year. The European Commission has already greenlighted a... Read more
2 related stories
30d
San Antonio Express-News
Amgen Inc. vs. Celgene Corp.fell 9% year-over-year for bone marrow stimulant Neupogen. A couple of other ma
Amgen Inc. vs. Celgene Corp.
San Antonio Express-News / Posted 30 days ago
fell 9% year-over-year for bone marrow stimulant Neupogen. A couple of other major drugs in Amgen's lineup, Aranesp and Neulasta, saw sales grow -- but only by low single-digit percentages. With patents expiring for Epogen and Neulasta, expect... Read more

People in this news